Trial reportPrenatal diagnosis2012
Integration of microarray technology into prenatal diagnosis: counselling issues generated during the NICHD clinical trial.
Trial report in Prenatal diagnosis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- An economic analysis of prenatal cytogenetic technologies for sonographically detected fetal anomalies.American journal of medical genetics. Part A · 2014Pooled it
- Trial
- Development and temporal validation of a multimodal post-test risk stratification model for pregnancies with abnormal prenatal findings.Scientific reports · 2026Article
- Article
- Reappraisal of evolving methods in non-invasive prenatal screening: Discovery, biology and clinical utility.Heliyon · 2023Review
- Decision-making for prenatal genetic screening: how will pregnant women navigate a growing number of aneuploidy and carrier screening options?BMC pregnancy and childbirth · 2021Article
- The impact of the emergence of COVID-19 on women's prenatal genetic testing decisions.Prenatal diagnosis · 2021Article
- Copy number variations in ultrasonically abnormal late pregnancy fetuses with normal karyotypes.Scientific reports · 2020Article
- Exploring the Issues Surrounding Clinical Exome Sequencing in the Prenatal Setting.Journal of genetic counseling · 2018Article
- Clinical utility of array comparative genomic hybridisation in prenatal setting.BMC medical genetics · 2016Article
- Prenatal SNP array testing in 1000 fetuses with ultrasound anomalies: causative, unexpected and susceptibility CNVs.European journal of human genetics : EJHG · 2016Article
- Article
- Counseling Challenges with Variants of Uncertain Significance and Incidental Findings in Prenatal Genetic Screening and Diagnosis.Journal of clinical medicine · 2014Review
- The Psychological Challenges of Replacing Conventional Karyotyping with Genomic SNP Array Analysis in Prenatal Testing.Journal of clinical medicine · 2014Review
- Fetal diagnostic indications for second and third trimester outpatient pregnancy termination.Prenatal diagnosis · 2014Article
- Microarrays as a diagnostic tool in prenatal screening strategies: ethical reflection.Human genetics · 2014Article
- Recent advances in the prenatal interrogation of the human fetal genome.Trends in genetics : TIG · 2013Review
- Women's experiences receiving abnormal prenatal chromosomal microarray testing results.Genetics in medicine : official journal of the American College of Medical Genetics · 2013Article
- Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context.Human reproduction (Oxford, England) · 2012Article
- Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies.Prenatal diagnosis · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Cytogenetic microarray analysis (CMA) in prenatal testing detects chromosome abnormalities and new genetic syndromes that would be missed by conventional cytogenetics and has the potential to significantly enhance prenatal genetic evaluation. A large Eunice Kennedy Shriver National Institute Of Child Health and Human Development (NICHD)-sponsored multicentered trial to assess the role of CMA as a primary prenatal diagnostic tool has been completed, and results will soon be available. Integration of this technology into clinical care will require thoughtful changes in patient counseling. Here, we examine four cases, all ascertained in the NICHD prenatal microarray study, to illustrate the challenges and subtleties of genetic counseling required with prenatal CMA testing. Although the specifics of each case are distinct, the underlying genetic principles of uncertainty, variable expressivity, and lack of precise genotype-phenotype correlation are well known and already part of prenatal counseling. Counselor and practitioner education will need to include both the science of interpreting array findings as well as development of improved approaches to uncertainty. A team approach to interpretation will need to be developed, as will standardized guidelines by professional organizations and laboratories. Of equal import is additional research into patient attitudes and desires, and a better understanding of the full phenotypic spectrum of copy number variants discovered in utero.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.